Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Adjustment Trial of Upacicalcet (SK-1403) in SHPT
NCT03226171Phase 2Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of upacicalcet in secondary hyperparathyroidism (SHPT), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoint: Rate of patients who achieved serum PTH between 60 pg/mL and 240 pg/mL at 18 weeks. Started Jun 2017; status: completed.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03226171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226171.